title: EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
abstract: Primary cutaneous CD30(+) lymphoproliferative disorders (CD30(+) LPDs) are the second most common form of cutaneous T-cell lymphomas and include lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Despite the anaplastic cytomorphology of tumor cells that suggest an aggressive course, CD30(+) LPDs are characterized by an excellent prognosis. Although a broad spectrum of therapeutic strategies has been reported, these have been limited mostly to small retrospective cohort series or case reports, and only very few prospective controlled or multicenter studies have been performed, which results in a low level of evidence for most therapies. The response rates to treatment, recurrence rates, and outcome have not been analyzed in a systematic review. Moreover, international guidelines for staging and treatment of CD30(+) LPDs have not yet been presented. Based on a literature analysis and discussions, recommendations were elaborated by a multidisciplinary expert panel of the Cutaneous Lymphoma Task Force of the European Organization for Research and Treatment of Cancer, the International Society for Cutaneous Lymphomas, and the United States Cutaneous Lymphoma Consortium. The recommendations represent the state-of-the-art management of CD30(+) LPDs and include definitions for clinical endpoints as well as response criteria for future clinical trials in CD30(+) LPDs.
authors.affiliation: Department of Dermatology, University Hospital Zürich, Zürich, Switzerland. werner.kempf@access.uzh.ch
authors.forename: Werner
authors.initials: W
authors.lastname: Kempf
authors.forename: Katrin
authors.initials: K
authors.lastname: Pfaltz
authors.forename: Maarten H
authors.initials: MH
authors.lastname: Vermeer
authors.forename: Antonio
authors.initials: A
authors.lastname: Cozzio
authors.forename: Pablo L
authors.initials: PL
authors.lastname: Ortiz-Romero
authors.forename: Martine
authors.initials: M
authors.lastname: Bagot
authors.forename: Elise
authors.initials: E
authors.lastname: Olsen
authors.forename: Youn H
authors.initials: YH
authors.lastname: Kim
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
authors.forename: Nicola
authors.initials: N
authors.lastname: Pimpinelli
authors.forename: Sean
authors.initials: S
authors.lastname: Whittaker
authors.forename: Emmilia
authors.initials: E
authors.lastname: Hodak
authors.forename: Lorenzo
authors.initials: L
authors.lastname: Cerroni
authors.forename: Emilio
authors.initials: E
authors.lastname: Berti
authors.forename: Steve
authors.initials: S
authors.lastname: Horwitz
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
authors.forename: Joan
authors.initials: J
authors.lastname: Guitart
authors.forename: Teresa
authors.initials: T
authors.lastname: Estrach
authors.forename: José A
authors.initials: JA
authors.lastname: Sanches
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
authors.forename: Annamari
authors.initials: A
authors.lastname: Ranki
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dreno
authors.forename: Sonja
authors.initials: S
authors.lastname: Ostheeren-Michaelis
authors.forename: Robert
authors.initials: R
authors.lastname: Knobler
authors.forename: Gary
authors.initials: G
authors.lastname: Wood
authors.forename: Rein
authors.initials: R
authors.lastname: Willemze
mesh_terms: D016022:Case-Control Studies; D015331:Cohort Studies; D005062:European Union; D006801:Humans; D017730:Ki-1 Antigen; D054446:Lymphoma, Primary Cutaneous Anaplastic Large Cell / Q000175:diagnosis / Q000628:therapy*; D017731:Lymphomatoid Papulosis / Q000175:diagnosis / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012955:Societies, Medical; D014481:United States
chemical_list: D017730:Ki-1 Antigen